drugset / Trial / NCT06022744

An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With nAMD

NCT06022744 ↗

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of intravitreal injection of LX109 in patients with nAMD.

Timeline

Start
2023-09-01
Primary completion
2025-09-30
Completion
2027-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject LX109 Gene therapy (AAV / viral vector) 7e+09 vg Intravitreal
Subject LX109 Gene therapy (AAV / viral vector) 3.5e+10 vg Intravitreal

Indications

No indication recorded.